Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Update

Enliven Therapeutics, Inc. (NASDAQ:ELVN) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 6,910,000 shares, a growth of 6.1% from the October 15th total of 6,510,000 shares. Approximately 23.8% of the company’s shares are sold short. Based on an average trading volume of 236,300 shares, the short-interest ratio is currently 29.2 days.

Analyst Upgrades and Downgrades

ELVN has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a research report on Tuesday, October 1st. Robert W. Baird increased their target price on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday.

Enliven Therapeutics Stock Up 2.3 %

Shares of NASDAQ ELVN traded up $0.57 during trading hours on Tuesday, reaching $25.47. 134,746 shares of the stock traded hands, compared to its average volume of 259,584. The company has a market capitalization of $1.24 billion, a P/E ratio of -13.16 and a beta of 1.08. Enliven Therapeutics has a 52-week low of $9.80 and a 52-week high of $30.03. The company’s 50-day simple moving average is $26.32 and its two-hundred day simple moving average is $24.05.

Insider Buying and Selling

In related news, insider Joseph P. Lyssikatos sold 12,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $22.49, for a total transaction of $269,880.00. Following the transaction, the insider now owns 1,077,936 shares of the company’s stock, valued at approximately $24,242,780.64. This trade represents a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Benjamin Hohl sold 6,250 shares of the firm’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $28.56, for a total transaction of $178,500.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 152,195 shares of company stock valued at $4,091,454. Insiders own 29.20% of the company’s stock.

Institutional Trading of Enliven Therapeutics

Large investors have recently made changes to their positions in the stock. Quest Partners LLC grew its stake in shares of Enliven Therapeutics by 87.3% during the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after acquiring an additional 742 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Enliven Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock valued at $232,000 after acquiring an additional 3,559 shares during the last quarter. EntryPoint Capital LLC purchased a new position in shares of Enliven Therapeutics in the 1st quarter worth $167,000. SG Americas Securities LLC purchased a new position in Enliven Therapeutics in the third quarter worth about $256,000. Finally, Verition Fund Management LLC bought a new position in shares of Enliven Therapeutics during the 3rd quarter valued at approximately $271,000. 95.08% of the stock is currently owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.